Evaluation of Industry Relationships Among Authors of Otolaryngology Clinical Practice Guidelines

Horn, Jarryd; Checketts, Jake X.; Jawhar, Omar; Vassar, Matt

doi:10.1001/jamaoto.2017.2741

Cited by 56 publications

(72 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…All 3 ACR guidelines adhered to the ACR requirement of having a principal investigator and literature review leader that were conflict‐free, as well as the requirement that the CPG development group be composed of fewer than 51% of authors with conflicts . Our findings—that authors of ACR CPGs have extensive industry financial relationships—parallel the findings of similar, previous investigations in dermatology , orthopedic surgery , urology , otolaryngology , oncology , and gastroenterology .…”

Section: Discussionsupporting

confidence: 88%

“…US‐based physician‐authors not found in the OPD were assumed to have not received industry payments. We excluded all food and beverage transactions, as this is consistent with the approach taken in previous studies . Payments were extracted in a parallel and blinded manner by 2 investigators (CW and ZZ) using the data download feature on the OPD.…”

Section: Methodsmentioning

confidence: 99%

“…Accordingly, CPGs with rigorous methods written by authors who are free from undue outside influences can be beneficial to patients and physicians . However, it has been shown many times that authors of professional society CPGs receive large sums of money from industry drug companies, thus creating financial conflicts of interest (FCOIs) . In a 2011 report, the National Academy of Medicine (previously, the Institute of Medicine) recommended that “whenever possible,” members participating in the development of CPGs should have no conflicts, which may require professional societies to seek out nonconflicted experts, although, in practice, many societies aim to manage, rather than eradicate, the influence of FCOIs.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Evaluation of Financial Conflicts of Interest Among Physician‐Authors of American College of Rheumatology Clinical Practice Guidelines

Wayant

Walters

Zaaza

et al. 2020

Arthritis & Rheumatology

Self Cite

View full text Add to dashboard Cite

Objective Clinical practice guidelines (CPGs) underpin patient care, and ideally authors of these guidelines would be free from outside influence. However, it has been shown many times that authors of professional society CPGs receive large sums of money from industry drug companies, creating financial conflicts of interest. This study investigated industry payments catalogued in the Open Payments Database (OPD) that have been received by authors of the American College of Rheumatology (ACR) CPGs. Methods Guidelines on the ACR web site that were published during or after August 2014 were used to retrieve the list of authors. All general, research, associated research, and ownership payments reported on the OPD between the date of publication of the CPG and 12 months prior were extracted in a parallel and blinded manner by 2 investigators. Results Of the 89 US‐based physician‐authors from the 5 ACR CPGs identified within the study timeframe, 56 (62.9%) had received at least 1 payment according to OPD records. These 56 authors had received a median of $522 (interquartile range $119–2,500), which, combined, was a total of $9,728,751. Nineteen authors had received at least 1 industry payment relevant to the CPG recommendations, for a median amount of $748 and a total of $1,961,362 in relevant payments. Of the total relevant payments received, a significant proportion was undisclosed (for ACR CPGs during or after August 2014, undisclosed payments were $699,561, or 35.7% of the total). Conclusion Fewer than one‐half of the US‐based physician‐authors of ACR CPGs during or after August 2014 had received guideline‐relevant industry payments. Nonetheless, a substantial proportion of the money received was not disclosed. Conflict of interest disclosure is a bare minimum requirement, and more permanent solutions may include divestiture or inclusion of more nonconflicted authors.

show abstract

Section: Discussionsupporting

confidence: 88%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of Financial Conflicts of Interest Among Physician‐Authors of American College of Rheumatology Clinical Practice Guidelines

Wayant

Walters

Zaaza

et al. 2020

Arthritis & Rheumatology

Self Cite

View full text Add to dashboard Cite

show abstract

“…87 The authors of this study also found that many CPG author disclosures were not captured in the database, suggesting either that the payments are underreported in the Open Payments database or perhaps that the data are somehow unreliable. Other studies have found that Industry payments are common and/or disclosures incomplete for CPG authors in orthopedics, 88 otolaryngology, 89 dermatology, 90 cardiology, 91 cancer, 92 pulmonary disease, 93 interventional medicine, 94 and psychiatry, 95,96 but this list is likely incomplete. Discordant disclosure for authors of CPGs is particularly problematic given the potential for these guidelines to influence national or international practice.…”

Section: Discordant Disclosurementioning

confidence: 99%

Ethical Issues Pertaining to Conflicts of Interest Between Neurologists and the Pharmaceutical and Medical Device Industries

Robbins

2018

Semin Neurol

View full text Add to dashboard Cite

A conflict of interest (COI) exists when a physician's professional responsibilities are compromised by personal or financial relationships. COIs between physicians and the pharmaceutical or medical device industry (Industry) are common. Collaborations with Industry have many potential benefits, but also raise potential ethical pitfalls. Industry-related COIs have widespread influence on medical education, research, and clinical practice, and therefore have profound implications for the integrity of the field of medicine. Full disclosure is an important step toward mitigating COI but does not redress subconscious accompanying biases. I review the spectrum of potential COI faced by physicians, with a focus on the ethics surrounding the relationship between neurologists and Industry. Other financial and nonfinancial COIs that influence neurologists and nonindividual entities, such as academic institutions, medical journals, and professional societies, are also discussed. Solutions ranging from disclosure to avoidance and recusal are briefly considered.

show abstract

“…There are, however, few data on the extent of undisclosed financial ties of guideline writers. One study of North American cholesterol and diabetes guidelines estimated 11% of writers had undisclosed ties,4 another study of American head and neck surgery guidelines found 6% had discrepancies between disclosures and an open payments database,5 while a Danish study of 14 specialty society guidelines found 52% had undisclosed ties 6. (For consistency, the term guideline writer is used throughout to refer to those who develop, draft and author guidelines.…”

Section: Introductionmentioning

confidence: 99%

Undisclosed financial ties between guideline writers and pharmaceutical companies: a cross-sectional study across 10 disease categories

et al. 2019

View full text Add to dashboard Cite

ObjectivesTo investigate the proportion of potentially relevant undisclosed financial ties between clinical practice guideline writers and pharmaceutical companies.DesignCross-sectional study of a stratified random sample of Australian guidelines and writers.SettingGuidelines available from Australia’s National Health and Medical Research Council guideline database, 2012–2014, stratified across 10 health priority areas.Population402 authors of 33 guidelines, including up to four from each area, dependent on availability: arthritis/musculoskeletal (3); asthma (4); cancer (4); cardiovascular (4); diabetes (4); injury (3); kidney/urogenital (4); mental health (4); neurological (1); obesity (1). For guideline writers with no disclosures, or who disclosed no ties, a search of disclosures in the medical literature in the 5 years prior to guideline publication identified potentially relevant ties, undisclosed in guidelines. Guidelines were included if they contained recommendations of medicines, and writers included if developing or writing guidelines.Main outcome measuresProportions of guideline writers with potentially relevant undisclosed financial ties to pharmaceutical companies active in the therapeutic area; proportion of guidelines including at least one writer with a potentially relevant undisclosed tie.Results344 of 402 writers (86%; 95% CI 82% to 89%) either had no published disclosures (228) or disclosed they had no ties (116). Of the 344 with no disclosed ties, 83 (24%; 95% CI 20% to 29%) had potentially relevant undisclosed ties. Of 33 guidelines, 23 (70%; 95% CI 51% to 84%) included at least one writer with a potentially relevant undisclosed tie. Writers of guidelines developed and funded by governments were less likely to have undisclosed financial ties (8.1%vs30.6%; risk ratio 0.26; 95% CI 0.13 to 0.53; p<0.001).ConclusionsAlmost one in four guideline writers with no disclosed ties may have potentially relevant undisclosed ties to pharmaceutical companies. These data confirm the need for strategies to ensure greater transparency and more independence in relationships between guidelines and industry.

show abstract

Evaluation of Industry Relationships Among Authors of Otolaryngology Clinical Practice Guidelines

Cited by 56 publications

References 31 publications

Evaluation of Financial Conflicts of Interest Among Physician‐Authors of American College of Rheumatology Clinical Practice Guidelines

Evaluation of Financial Conflicts of Interest Among Physician‐Authors of American College of Rheumatology Clinical Practice Guidelines

Ethical Issues Pertaining to Conflicts of Interest Between Neurologists and the Pharmaceutical and Medical Device Industries

Undisclosed financial ties between guideline writers and pharmaceutical companies: a cross-sectional study across 10 disease categories

Contact Info

Product

Resources

About